Animalcare has launched Emdocam (meloxicam 20mg/ml), a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class for use in cattle, pigs and horses.
According to the company, Emdocam disrupts the inflammatory cascade by inhibiting prostaglandin synthesis. It is a potent and preferential inhibitor of COX-2, permitting sufficient COX-1 sparing activity. It has analgesic and anti-inflammatory effects. When administered in a single dose to cattle, it has long acting anti-endotoxic, anti-pyretic and anti-inflammatory effects for up to three days.1,2
In cattle, it is indicated for bovine respiratory disease (BRD), clinical mastitis and calf scour. Animalcare says early use of meloxicam for BRD reduces pyrexia and pain, especially in young calves and improves feed intake. Meloxicam plus an antibiotic significantly reduced the extent of lung lesions, leading to improved clinical efficacy and daily liveweight gain in comparison with animals treated with antibiotics alone, for example oxytetracycline,3 florfenicol4and tilmicosin. 5
In the case of clinical mastitis, Animalcare says that used adjunctively with an antibiotic, Emdocam helps relieve local and systemic inflammation, returns the udder to a normal condition and reduces the polymorphonuclear leucocytes (PMN) response. In a large scale, double-blinded study in New Zealand, the addition of meloxicam to antibiotic therapy resulted in lower Somatic Cell Counts and a reduced risk of culling in dairy cows with mild clinical mastitis.6
Calf scour treated with meloxicam, as a supportive therapy, can improve calf well-being and reduce morbidity. In a double-blinded, controlled study, the use of meloxicam improved daily water and feed intake, added greater average bodyweight (bw) gain and helped calves to wean earlier. 7
In horses, administered IV at 3.0ml/100kg bw, Emdocam can be used for musculo-skeletal disorders, as well as colic, resulting in reduced pain and inflammation. In a study of 18 horses comparing flunixin with meloxicam and designed to determine the effect on recovery of ischemic-injured jejunum, meloxicam was found to be a useful alternative for the post-operative treatment of colic. 8
Emdocam is also indicated in pigs for non-infectious locomotive disorders and as an adjunctive therapy with an antibiotic in puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).
Tony Liepman from Animalcare said: "Emdocam is competitively priced whether used on its own or adjunctively with a long-acting intramuscular (IM) antibiotic, such as Florgane suspension for the treatment of BRD in calves. This, coupled with its long lasting, low volume (2.5ml/100kg bw in cattle), single dose administration, by intravenous (IV) or subcutaneous (SC) injection, makes Emdocam a highly efficacious and practical NSAID."
Emdocam is a POM-V medicine and available as 50 and 100ml multi-dose vials. Withdrawal period in cattle for meat and offal is 15 days and in pigs for meat and offal is 5 days. In horses for meat and offal it is 5 days. In Florgane [POM-V], the withdrawal period for meat and offal is 37 days in cattle and not to be used in cattle producing milk for human consumption
References
Cattle
The company says Salmoporc has been used on German and Polish farms for over 15 years and has proved to be safe and effective in controlling salmonella.
The vaccine can be administered orally in piglets and via subcutaneous injection in sows.
Company vet Dr Rike Schmelz said: "Salmonella in pigs is growing threat and an important zoonotic disease. According to the 2018 European Food Safety Authority (EFSA) report, salmonellosis is the second most reported zoonosis in Europe with over 90,000 cases reported in humans.
"Salmonella typhimurium and monophasic Salmonella typhimurium represented 17 per cent of confirmed human cases in 2017 so constitutes a major risk to humans."
VetSurgeon.org understands the new vaccine is expected in the UK sometime after October, before which it can be obtained under a Special Import Certificate.
Using practices developed for human healthcare measurement, NewMetrica developed VetMetrica, which the company says can measure how an animal “feels” about its circumstances from its individual perspective.
Jim Brick, Vice President Commercial Development and Lifecycle and Innovation at Zoetis said: "This novel approach supports a significant shift in veterinary care and animal welfare more generally towards the attainment of good or excellent quality of life in companion animals.
"The benefits of NewMetrica’s digital instruments have been validated through scientific publications and the FDA, and the EMA has confirmed the algorithms that produce the results.”
Jamie Brannan, President International Operations, Zoetis added: "We expect NewMetrica’s tools and algorithms to support earlier detection and treatment of diseases as we gain more insight into the quality of life of our pets and be an important element of future product development.
“NewMetrica’s instruments will give us scientifically validated results for alleviation of OA pain that veterinarians and pet owners will appreciate and value.”
https://www.newmetrica.com
The Apple iPad made its UK debut last week. I queued outside the Apple shop for over 15 minutes (well, it was Salisbury, not Regent Street) on launch day to get my hands on one of the first and review it for VetSurgeon members.
For those that don't have the time for long-winded reviews, I'll come straight to the point: buy one, you won't regret it. Even if you get home and decide you have no use for a tablet computer, you could probably put it on ebay and turn a small profit. But you won't. You'll just keep finding more reasons why the iPad is an indispensable piece of kit.
I won't dwell on the technical specifications of the thing. All you really need to know is that it's a touchscreen tablet computer about the size of a small hardback, though it weighs a little more. I don't know (or care) what sort of chip it contains. Whatever it is, it's more than capable of handling the tasks the iPad is designed to do, effortlessly.
So why is the iPad a 'must have'? Because it transforms the experience of browsing the Internet, reading email etc. from being a bit of a hassle, to being as simple and quick as, er, picking up and opening a book. I think the best way to illustrate my point is to describe the uses I've found for it in the first 4 days of ownership:
BrowsingI wanted to know what's on locally for children this weekend. Normally I'd have to go and power up the computer upstairs. Not anymore. Now I just pick the iPad up off the kitchen table. It wakes instantaneously, and the browser opens at the press of a button. Incidentally, once I'd found the Sherborne Fair, it was only another couple of clicks before it was displayed on the built-in map, along with an estimated time to get there. In my case, it also makes my job easier - I can dip into the VetSurgeon and VetNurse forums much more easily when away from my desk (something I intend to be more of, from now on).
EmailNot much to say, except that once again, it's a pleasure to be able to check my email at the press of a button, rather than having to go upstairs and power up my desktop, or wait whilst my wife's interminably slow laptop gets its act together. No, the touch screen keyboard is not quite as well suited to the task as a normal keyboard. Having said that, I typed half this article on my iPad last night at very nearly the same two-handed speed as I would have on my desktop.
Read the newspaperThe Times is now available on the iPad for £9.99 per month. You just press the download button any time after 7:00am, and a few minutes later it appears on the screen. If you fall into the camp that says: 'it'll-never-catch-on-....-nothing'll-replace-the-feel-of-a-book-or-a-newspaper', I wouldn't have argued with you a week ago. Now I would. The iPad version is beautifully intuitive, and a pleasure to read. Despite a few grumbles (where is The Sunday Times?), I'll be cancelling my print subscription.
PhotographsThis is really the first viable alternative to the traditional print photograph album. And it's not just an alternative, it's a far superior way of storing and retrieving photographs. The iPad's high quality display means your pictures really leap off the screen. Its portability and ease of access mean that you might actually look at your photos and share them with others from time-to-time, rather than leaving them to gather dust in a box, or sit in an unvisited folder on your computer. I'm digitising 20 year's worth of photographs for this reason.
Other uses and appsThe list of software applications for the iPad is growing every day. Meantime, any app designed for the iPhone will also run on the iPad, though they don't make full use of the big screen. There are thousands of rather pointless apps, seemingly designed not to meet a need nobody knew they had. But amongst the rubbish, there are some genuinely useful apps out there:
A couple of minor irritations about the iPad. Currently it doesn't support the rich editing feature used by default when you post to the VetSurgeon forums, or elsewhere on the site. Fortunately, there's a quick workaround, which is to visit your VetSurgeon profile (My Account > Edit My Profile > Display Options tab) and set the Content Editor to 'Plain text'. Also, very occasionally the iPad freezes, at which point you have to press the On/Off and Home buttons together for six seconds to reset. Doubtless both these will be fixed in the next software update, due in the next month or two, I think.
The 'twitterati' has bemoaned the iPad's lack of hardware features and flexibility. There's nowhere to insert a DVD. No camera. No USB port. No card reader. But that rather misses the point. The iPad isn't a replacement for a desktop or laptop unless the only things you use a computer for are browsing and email. Anyone who wants to store and edit video, edit photographs, or create anything other than fairly basic documents or spreadsheets, still needs a bigger machine with USB ports and DVD drives galore. What the iPad does is free you from having to browse electronic media at a desk. And it does so in such user-friendly way that I'll be ordering one for my Mum (aged 62) and my grandmother (aged 92).
There are six models available. Three memory sizes: 16GB, 32GB and 64GB with either wi-fi Internet access, or wi-fi plus 3G mobile phone access. Prices from £429 to about £700 (to which you'll need to add the cost of a protective wallet). I plumped for the 64GB memory (probably overkill), wi-fi only model, on the basis that there are enough BT Openzone wi-fi hotspots now to mean I'll never be far from one.
I'm not normally one for hyperbole. But in this case, I'll forgive Mr. Jobs calling the iPad 'a magical and revolutionary product'.
It is.
Dogs with RVED develop retinal degeneration from around four years of age which, if untreated, leads to blindness.
In partnership with James Oliver, Head of Ophthalmology at DWR Veterinary Specialists (pictured), researchers set out to discover why some Cocker Spaniels have such low vitamin E levels in their blood, despite it being present at normal amounts in their diet
James helped to design the study, recruit cases and collect samples.
Cathryn Mellersh, Senior Research Associate at the Canine Genetics Centre, said: “The team strongly suspected a genetic cause and has been trying to discover the responsible gene for several years with the help of owners and vets, who have contributed DNA samples.
“Thanks to updated information on the canine genome, Katherine Stanbury, one of our research associates, found a mutation in the alpha tocopherol transfer protein gene which is causative of the disease.
“This gene is responsible for getting vitamin E into the blood stream.
"We now know that RVED is a recessive disease, meaning that affected dogs must have two copies of the faulty gene to develop low vitamin E levels and retinal degeneration.”
The team’s DNA test can be used by dog breeders to find out if dogs carry the gene mutation, so they can avoid matings which result in affected puppies being born.
Cathryn said: “This DNA test is a rare example of one which not only can be used to identify dogs that are carrying the mutation and thus reduce the frequency of the mutation in future generations, but also has the incredible benefit of providing a sight-saving treatment option for dogs with the disease.
“From the research we have done we estimate that there could be several hundred Cocker Spaniels alive today that have two copies of this mutation, whose eyesight could be saved by this test.”
A DNA test for the mutation that causes RVED is now available from Canine Genetics Testing, which operates alongside researchers from the Canine Genetics Centre.
www.cagt.co.uk.
The team’s RVED research can be viewed at https://academic.oup.com/g3journal/advance-article/doi/10.1093/g3journal/jkaf016/7985679?searchresult=1
In the past, few employers in the veterinary profession have chosen to advertise salary details, perhaps because they don't want to open a negotiation with their cards on the table, or perhaps they've been fearful of their existing employees finding out what they're prepared to offer a new candidate.
In the VetSurgeon forums, some employers have also remarked that the job isn't about money, and they wouldn't be interested in a candidate whose search criteria included the salary on offer.
The reality, of course, is that we all have bills to pay, children to feed or mortgages to cover and whilst few if any veterinary surgeons search for a job on the basis of salary alone, it's perfectly reasonable that the salary is part of their deliberations.
More than that, all the indications are that job advertisements which include salary details generate more, better qualified responses. Reed carried out a survey of 1000 jobseekers in 2016, 2/3rds of whom said they would be more likely to apply when a salary is displayed on the advert. Another company, Smart Recruit Online, found back in 2013 that job adverts which included a salary generated 30% more responses that those that didn't.
There are also indications that in the future, Google may start to prioritise jobs advertised with salary information in its search results.
To try and strike a balance between some employers' reluctance to display what they might be prepared to pay and the need for greater transparency, advertisers can now display a 'Minimum Offer' on VetSurgeon Jobs, described to the potential applicant as: "The minimum this employer is prepared to offer someone with the skills and experience needed to fulfil the job requirements. They may or may not be prepared to offer more. They may also be prepared to accept someone with a lower level of qualification or experience for an amount less than displayed."
Alternatively, employers can advertise a 'Pay Range', described to potential applicants as: "The employer expects to pay something within the displayed range, depending on their assessment of the value of the applicant's skills and experience to the practice."
In addition, employers can also display other benefits which are likely to be of more or less value to individual applicants, such as a RCVS fees, association subscriptions, health insurance and CPD allowances.
VetSurgeon.org Editor Arlo Guthrie said: "This is entirely optional, but I do hope as many employers as possible will make good use of this new feature, because all the research and anecdotal evidence suggests it’s what candidates want to hear, and it should lead to a better response. Not to mention how time-saving it is for two people to come to the table with realistic expectations."
Virbac has has announced the launch of Buprevet, a buprenorphine-based, injectable solution indicated for the potentiation of sedative effects of centrally-acting agents in dogs and for use in cats and dogs as part of a multimodal approach to analgesia.
Buprevet is presented in a 10 ml multi-dose bottle which can be broached up to 25 times and can be open for up to 28 days.
Sarah Walker MRCVS, Product Manager, said: "Buprenorphine is a potent, high affinity, synthetic opioid agonist which forms a key element of practice anaesthetic protocols and complements our existing anaesthetic range. Its potentiation effects means less sedation is needed in the pre-medication and in the anaesthesia, facilitating smoother recoveries with more comfortable patients."
"Buprenorphine is a tried and trusted solution for analgesia in many practices. Buprevet can be given pre-operatively to allow analgesia during and after surgery. It works effectively as part of a pre-emptive approach to analgesia, alongside products such as Inflacam and Carprox in our NSAIDs range."
Dechra Veterinary Products has launched TAF Spray (thiamphenicol), a next generation antibiotic wound spray for superficial wound infections in horses, cattle, goats, sheep and pigs.
Dechra says TAF Spray can also be used to treat infections of the claw and hoof in cattle, goats and sheep such as foot rot, interdigital dermatitis and digital dermatitis.
TAF Spray is the only licensed wound spray for horses and has a zero day meat withdrawal period for horses, cattle, goats, sheep, and 14 days for pigs.
Dechra is also highlighting the fact that TAF Spray is the only golden yellow coloured product of its kind on the market, allowing treatment areas to be distinguished clearly.
Brand Manager Emma Jennings said: “Dechra has developed TAF Spray in direct response to the research we conducted among farmers".
The research1 showed that 51% of the veterinary surgeons had used an antibiotic spray for the treatment of digital dermatitis – an infection that 92% of farmers had experienced in their livestock in the past 12 months.
Emma added: "Thiamphenicol is a highly effective antibiotic. With the brightly coloured spray format making it distinguishable from other treatments and a can that is able to be used in upright and inverted positions, we are sure that TAF Spray will become a popular product among veterinary professionals.”
TAF Spray comes in a 150ml can with a 360-degree nozzle which allows wounds to be targeted at any angle.
For further information about Dechra’s antibiotic portfolio, visit www.dechra.co.uk
Reference
The Disciplinary Committee heard four charges against Dr Schulze Allen.
The first charge related to the original criminal conviction in the County of San Bernardino in California dating from September 2013, where Dr Schulze Allen pleaded guilty to petty theft for which he was fined US $435 and ordered to pay a fee of US $35.
The second charge related to the fact that, on or around 3 December 2013 in a written application for restoration to the Register, Dr Schulze Allen was dishonest in representing that he did not have any cautions or criminal convictions.
The third charge related to the fact that on or around 4 December 2013 in a sworn affidavit before a Notary Public in Riverside, California, he dishonestly and falsely represented that he had, at no time, been convicted of a criminal offence in the UK or elsewhere.
The final charge was that, in an email to the RCVS in June 2016, he dishonestly and falsely represented that he had "no criminal record whatsoever".
Having found Dr Schulze Allen guilty of all four charges the Committee then considered whether the conviction rendered him unfit to practise veterinary surgery and whether the remaining charges amounted to disgraceful conduct in a professional respect.
The Committee noted that the conviction was for a minor matter but had regard to all the evidence before it and considered that as an offence of dishonesty it represented a breach of one of the fundamental tenets of the profession. It further considered that Dr Schulze Allen’s dishonesty toward the College and his completing a legal document which he knew would be relied upon by the College was conduct that fell far short of the standard expected of a member of the profession.
With regard to the final charge, the Committee considered this a "clear attempt to deliberately misrepresent the fact that he had a conviction for a criminal offence." The Committee considered that Dr Schulze Allen’s conduct had been aggravated by the fact that it was protracted and repeated over a period of time.
Ultimately the Committee considered that the conviction rendered Dr Schulze Allen unfit to practise veterinary surgery and the remaining charges amounted to disgraceful conduct in a professional respect.
Ian Green, chairing the Committee and speaking on its behalf, said: "His conduct represented a blatant disregard of the role of the RCVS and the systems that regulate the veterinary profession. The Committee also remained particularly concerned at Dr Schulze Allen’s very limited insight into his conduct."
He added: "In mitigation the Committee noted that this is not a case where harm was caused to any animals or humans. It noted that prior to these matters which are before the Committee that Dr Schulze Allen had an unblemished career and that he had been of good character. In respect of purely personal mitigation the Committee noted that Dr Schulze Allen is the main breadwinner of the family."
However, the Committee considered that Dr Schulze Allen’s conduct had fallen significantly short of standards expected of a veterinary surgeon.
Ian Green concluded: "The Committee considered that the only appropriate sanction is that of removal from the Register. Such a sanction is required to send a clear message to Dr Schulze Allen and to veterinary surgeons of the unacceptability of being dishonest to the RCVS. Such conduct undermines public confidence in the profession and fails to uphold proper standards of conduct and behaviour.
"Accordingly, the Committee has decided that removal from the Register is appropriate and proportionate in this case. The Committee will direct the Registrar to remove the respondent’s name from the Register forthwith."
Dr Schulze Allen has 28 days from the date of the decision to appeal the Committee’s decision.
The Committee’s full findings and decision is available at www.rcvs.org.uk/disciplinary.
ISFM points to an editorial published ten years ago in The Lancet (Hypertension: uncontrolled and conquering the world), which presented alarming facts about hypertension in people: the risk of becoming hypertensive during a lifetime exceeds 90% for people in developed countries, with over 1.5 billion adults expected to have hypertension by 2025. It also said: 'screening is not done systematically, and the diagnosis is often made at a late stage when target organ damage has already happened'.
The Society says there are broadly similar concerns in our feline companions. Hypertension is a well-recognised condition in older cats, yet probably remains significantly underdiagnosed. The consequences can be severe, with target organ damage typically affecting the eyes, heart, brain and kidneys. Some damage, such as blindness resulting from complete retinal detachment, is irreversible. Other damage, however, is more amenable to antihypertensive treatment, highlighting the importance of early diagnosis and intervention. However, this presents challenges, particularly as routine blood pressure monitoring is generally performed infrequently in cats. Furthermore, cats are notoriously susceptible to stress in the veterinary clinic, which can lead to 'white coat hypertension' and hamper interpretation of results.
The new ISFM consensus guidelines are published in its Journal of Feline Medicine and Surgery1. The recommendations are those of an expert panel of veterinary clinicians and academics gathered from the UK, Australia, New Zealand, Spain, France and the USA, and cover several key areas. They include: how often to monitor blood pressure for cats of different ages and health status; when antihypertensive therapy is justified based on different systolic blood pressure readings and evidence of target organ damage; and what an investigation of hypertensive cats should include.
Samantha Taylor, a specialist in feline medicine and one of the co-chairs of the guidelines panel, said: "Well-illustrated and easy to read, it is hoped that these guidelines will encourage more widespread monitoring of blood pressure in veterinary clinics to increase the early identification of this treatable condition, and prevent the severe clinical consequences of untreated hypertension."
Accompanying the guidelines, which are endorsed by the American Association of Feline Practitioners, are further resources to assist veterinarians with the diagnosis of hypertension. A blood pressure evaluation form can be downloaded from the supplementary material; in addition, a series of short videos produced by the ISFM on measuring blood pressure in cats is available in various languages at https://www.youtube.com/user/iCatCare/playlists.
The survey, which received over 1300 responses, found that the problem is more noticeable amongst locum vets (69% have worked when they’ve not felt well enough) and employees (64%) but is also an issue amongst partners and the self-employed (57%). It’s more common for vets in clinical practice (65%) than in non-clinical roles (51%). In all of these sectors over half of vets reported working when they were unwell.
18% of the vets surveyed said they do not take sick leave because they feel uncomfortable doing so. This is more common amongst younger vets (25% of under 35s compared to 19% of 35-54-year olds, and 8% of over 55s) and female vets (21% compared to 11% of male vets).
The main reasons given for not taking time off when sick are concerns about the impact on colleagues and worries about "letting the team down". One respondent said: "Because I would leave the practice understaffed and the remaining vets would have to work a lot harder and longer as a result." Another said: "Being ill is not an option. The practice is short staffed."
Members also reported a perceived culture of working through sickness. One said: "The veterinary industry on the whole has a 'phone in dead' policy ie don't call in sick!" and another said: "[I] feel that I am judged for taking time off, even when I lost my voice and was unable to consult."
A small number of responses (36 of the 450 vets who commented) mentioned that they did not receive sick pay or only received limited sick pay, so they avoided taking sick leave for financial reasons.
The BVA is reminding all vets that they have a legal right not to attend work when they aren’t well enough do so and that any concerns should be discussed with managers. The free BVA legal helpline is available to members to provide further guidance on taking sick leave.
BVA President Daniella Dos Santos said: "We know that veterinary workplaces are under enormous pressure from staff shortages, and none of us wants to feel like we are letting our colleagues down, but presenteeism only stores up more problems for the future.
"Working when you are ill puts your own health and wellbeing at risk longer term and can also put your colleagues, clients and patients under your care at risk.
"It’s particularly worrying that some of our colleagues feel pressure to work when they feel unwell, especially younger members. As a profession we have made huge steps forward in recognising the issues around mental health and supporting one another and being physically unwell should be the same.
“Anyone who is concerned should speak to their manager and remember that BVA members can always get free advice and support via the BVA legal helpline. Ultimately, it’s important to create a workplace culture that supports the entire veterinary team to prioritise their own physical and mental health."
Photo: Javier Brosch / Shutterstock
177 delegates took part in the survey, which found that even the most commonly used digital tool, namely automated reminders, are not being used by more than a third of all practices.
Less than 60% are using digital records.
Less than half are using online booking, which Provet says can significantly improve the customer experience.
Less than 20% have implemented integrated payments or telemedicine or pet owner apps.
The survey also found that 42% are still using old server technology, rather than cloud-based solutions (28%).
The company has produced a guide to what you should look for in a practice management system, including pros and cons of cloud vs. server-based solutions and digital tools that can improve service level whilst saving time, which you can download here.
The study, which was led by the College's VetCompass programme, found that British bulldog ownership has increased from 0.35% of all puppies born in 2009 to 0.60% in 2013.
At the same time, the study found that British bulldogs suffer more than other breeds from a number of conditions associated with their aesthetic characteristics, including: skin fold dermatitis (7.8%), prolapsed gland of the third eyelid or 'cherry eye' (6.8%), interdigital cysts (3.7%), entropion or inward turning of the eyelid (3.6%), and corneal ulceration (3.1%).
Worse still, only 3.5% of the 1,621 British bulldogs analysed in the study were diagnosed with brachycephalic obstructive airway syndrome (BOAS), despite an earlier study reporting that 84.8% of tested Bulldogs are affected by BOAS to some extent, with 44.0% exhibiting clinically relevant disease2.
This, say the researchers, suggests owners consider breathing problems such as snoring as normal and are not therefore taking their dogs for needed check-ups.
Other findings included:
12.7% of British bulldogs suffer from ear infections, 8.8% from skin infections and 8.7% from obesity
Males are more likely than females to develop skin infection, interdigital cysts, atopic dermatitis and aggression, whereas females are more likely to develop dental disease and obesity.
The average adult bodyweight for a British bulldog is 26kg.
The average lifespan of bulldogs is 7.2 years.
The most common causes of death are heart disease (11.8%), cancer (10.9%) and brain disorder (9.1%).
The RVC says that the results of the study will support initiatives by the Kennel Club and the UK Bulldog Breed Club to improve breeding and also help owners and vets prioritise tackling the leading issues British bulldogs face.
Dr Dan O’Neill, VetCompass epidemiologist at the RVC and Chairman of the Brachycephalic Working Group, said: "The UK has seen unprecedented increases in the popularity of certain short-faced breeds over the past decade. This has led to a series of well-documented welfare issues relating to how these dogs are bred and sold for the UK pet-owning market, high levels of dumping of unwanted dogs into the UK charities and health problems that are intrinsically linked to the extreme body shape of these dogs.
"This new study gives firm evidence for the first time on the true levels of popularity and also of disease diagnosed in the wider population of bulldogs in the UK. This information can help to move the conversation on welfare from 'what are the issues' to 'how do we deal with these issues'. Reliable evidence is pivotal to good decision-making."
Dr Rowena Packer, BBSRC Research Fellow at RVC, said: "The bulldog is an iconic breed but concerns over the health problems allegedly facing these popular dogs have mounted in the past decade. It is extremely valuable to have solid data on the health problems facing this breed, confirming a number of inherent breed predispositions that need to be tackled.
This data supports current initiatives encouraging breed reform, particularly regarding health problems inherently related to their looks, and the need for selection for healthier body shapes. For example, skin fold dermatitis was common in bulldogs and is associated with the desired wrinkled face in this breed – this calls into question the justification of this and other such breed traits that put dogs at risk of potentially avoidable disease."
Steve Dean, Chairman of the Kennel Club Charitable Trust said: "The Kennel Club has put into place a number of crucial measures over the years to monitor, protect and improve bulldog health and to provide the many responsible breeders with the tools they need to do the same, but this paper highlights there is still work to be done."
The study is published open access in PLOS ONE.
References:
The idea for an interactive vaccination calendar was in fact first developed two years ago by Jon Reader MRCVS (pictured right) from Synergy Farm Health. With input and funding from Boehringer, it has now been developed into an online tool which highlights times when animals may be at risk if immunity has waned, without sufficient boosting of immunity by vaccination.
The transmission of BVD is complex and protecting the foetus from the virus is at the heart of any control programme. The virus is passed from dam to foetus and, if this occurs in the first third of pregnancy and the foetus goes to term, a persistently infected (PI) calf will be born. These will then go on to shed virus throughout their lives, so infecting herdmates and the next generation of calves.
Jon said: "The timing of when a vaccine is given is critical to the development of an immune response, which will protect the unborn foetus.
"Working out when you want the dam to calve and then calculating back shows when either a primary course of BVD vaccine or a booster should be given but, get this wrong and you will end up with what is known as an 'immunity gap'.
"It is vital that both heifers and cows have maximum protection during the breeding period and in early pregnancy."
Boehringer says heifers must be fully protected before being served for the first time, and cows must have had immunity boosted before they are pregnant again. However, far too often heifers are adequately protected following an initial booster but given their age and date of service, do not receive further protection until they enter the adult herd.
Jon said: "If heifers calve just after the herd booster, then there is a very real possibility that they will go for two years without a booster, and be severely exposed when they become pregnant as a first lactation heifer."
"This is termed the immunity gap; a period when the animal is not protected from the virus at all. The aim should be to eliminate this period completely, so that there is no immunity gap."
Matt Yarnall from Boehringer said: "Each BVD vaccine has its own timing protocol stating when the primary course should be given, as well as subsequent booster timing and when cows should be served. Moreover, some of these are not straightforward to follow, especially for year-round calving herds."
"Anyone using the Bovela vaccine has peace of mind that the one dose primary course combined with flexible booster regime and 12 months’ proven duration of immunity minimises the immunity gap."
For more information, visit: makebvdhistory.co.uk.
The apple-flavoured, gastro-resistant granules can be mixed with dry feed to make administration easier for owners.
Animalcare says that up to 37% of leisure horses and 93% of race horses are reported to be affected by gastric ulcers1, for which the most prescribed treatment is omeprazole.
Equizol’s granule formulation has been developed to support owners who find syringe administration difficult or wasteful. It is presented in packs of 28 sachets, each containing sufficient omeprazole to treat 200 kg body weight. Owners mix the appropriate number of sachets into a small amount of the horse’s feed.
Animalcare Product Manager James Beaumont said: “Offering innovative product solutions which better meet our customer’s needs is our goal and Equizol is a perfect example. Our established equine healthcare range includes products for pain management, infusion therapy and microchips. Now, with the launch of Equizol, we are offering an innovative, easy-to-use and cost-effective solution to the common problem of gastric ulcers, based on tried and trusted omeprazole. We are delighted to add it to our range.”
The study “Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom” used the Small Animal Veterinary Surveillance Network to review electronic health records equating to 3,150,713 consultations (917,373 dogs) from 224 veterinary practices2.
Five hundred and seventeen cases were included. Dogs older than 6 years were excluded.
Of 321 dogs presented for a single seizure, seven (2.1%) were prescribed AEDs, which is in accordance with International Veterinary Epilepsy Task Force recommendations.
20% of the dogs in this group which had at least a 6-month follow-up, 20% did not have subsequent seizures recorded.
However, of 86 dogs which had suffered a seizure cluster at first presentation, only 38 (44%) were prescribe an AED, despite the task force recommendation that long term treatment in dogs with idiopathic epilepsy should be started immediately in the case of 2 or more seizures within 6 months, status epilepticus or a seizure cluster, severe post-ictal signs, or a deteriorating epileptic presentation.
Imepitoin was frequently selected in the treatment of cluster seizures despite no authorisation for this purpose.
Nicola Di Girolamo, Editor of JSAP said: “Studies like this one are instrumental to understand how primary care clinicians comply with current recommendations.
"Additional efforts may be required to fully adhere to the International Veterinary Epilepsy Task Force recommendations; being aware of these gaps is the first step towards improvement.”
Baycox Iron Injection is indicated for the concurrent prevention of clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets on farms with a confirmed history of coccidiosis caused by Cystoisospora suis, and the prevention of iron deficiency anaemia.
Professor Nicole Kemper, Director of the Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour at the University of Veterinary Medicine Hannover in Germany said: "Piglets go through intense handling in their first days of life. While this is done to give them a better start to life and protect them from disease, it can also cause a lot of stress. Measures to reduce the need for piglet handling can make an important contribution to enhancing piglet well-being in the farrowing pen."
Octavio Orlovsky Eckhardt, Head of Species Marketing Swine at Animal Health, Bayer said: "A combination therapy that can effectively address these concerns with reduced handling can make a real difference for pig health and well-being.
"At the same time, farmers and workers can benefit from the reduced labour. For example, on a 1,000 sow farm, the reduced complexity is estimated to save up to one full work day every month."
For more information on Baycox Iron Injection, contact your local Bayer Animal Health representative.
Bovilis Nasalgen-C can be used for the active immunisation of calves from the day of birth onwards to reduce clinical signs of upper respiratory tract disease and nasal viral shedding from infection with BCoV.
MSD says respiratory disease in UK calves is widespread and comes at a high cost from an emotional and business productivity perspective.
It is also continually highlighted as a critical area for overuse of antibiotics.
Despite all this, there is an under use of vaccination in the UK cattle sector1.
Speaking at BCVA last week, Paul Burr MRCVS, director of Biobest Laboratories said: “Recent UK studies show bovine coronavirus being the most prevalent virus found in routine disease screening and nasal swab samples taken during a bovine respiratory disease outbreak.
"BCoV was found in 39% of over 400 nasal swab samples taken between 2020 and 2022 from BRD affected cattle on UK farms2.”
Kat Baxter-Smith, veterinary adviser with MSD Animal Health, said: “Whilst the pathogenicity of BCoV within the BRD complex remains an unknown quantity, its ubiquitous presence in the UK cattle population – and the recent human experience of coronavirus as a significant respiratory pathogen – suggests a need for a re-evaluation of BRD control by vets and farmers.
“Just as coronavirus is a pathogen associated with the common cold and Covid-19, BCoV is a proven pathogen that directly impacts the calf respiratory tract.
"Consequently, the availability of this new BRD vaccine presents veterinary professionals with another tool in their armoury to improve control of this costly disease.
“If diagnostics suggest BCoV is implicated in any BRD problem, the availability of Bovilis Nasalgen-C allows UK cattle farmers to effectively administer protection for young calves via a single 2ml intranasal dose that can quickly reach the site of action.
"This will support the development of immunity against BCoV early in life, the onset of which starts five days after administration and has a 12-week duration.”
Bovilis Nasalgen-C comes can be used on the same day with Bovilis INtranasal RSPÔ Live, which offers protection against both Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3).
Bovilis Nasalgen-C can be stored for up to 24 hours at room temperature after reconstitution, can be given to cattle using a syringe or applicator device and is available in one, five and 20 dose packs, suitable for both small and large herds.
Research shows that over 60% of cast-treated pets get additional injures, such as pressure sores, from traditional plaster casts1.
The new cast is designed to tackle these issues with anatomically shaped bi-valve splints that are based on 30,000 3D scans of animal limbs.
Upets TLC products are made from FDA and CE approved Woodcast material used in human casting and splinting.
Bandages, padding and tape are replaced with a soft, self-cohesive Unitex fabric that passes moisture and dries fast.
TLC products are engineered for easy destabilisation by removing parts of the splint, and the same product can be used throughout the whole treatment.
Orthopets, a subsidiary of the materials company Dassiet, says that breathable, lightweight materials combined with the anatomical fit help prevent sores and restore normal position and movement of the limb.
OrthoPets founder Martin Kaufmann said: “The common cast is very problematic, but we've lacked better alternatives. Now, with the Dassiet supermaterials and OrthoPets’ vast experience in veterinary biomechanics we have re-engineered the common cast.
"Upets TLC is anatomical and safe. It’s stress-free for both the vet and the pet. It brings veterinary casting to the modern day and offers a better standard care option for all vets and orthopaedic surgeons out there.”
"Sores, pain and stiffness are always on the horizon with casting. But if we take the cast off too early, the leg can be injured again because of lack of proper support. UPETS tackles these problems all at once. I find it easy to apply the pre-shaped casts even for very small or large dogs and make adjustments if needed. I can watch my patients walk off the clinic normally with their cast, knowing they can wear it safely until fully healed. We see significant and immediate improvement in patients compared to the common cast”, says Dassiet Chief Veterinarian Jouni Niemi, who oversees the clinical research of UPETS.
For more information, visit: www.upets.vet/TLC
The new practice was created by refurbishing the premises of what was a purpose-built human hospital, turning it into a referral clinic with two operating theatres, separate accommodation and waiting rooms for cats and dogs, offices and a seminar room.
Funding for the refurbishment came from NatWest, with further funds for things like digital radiography and a CT scanner coming from Lombard Asset Finance.
Martin said: "We decided to open East of England Veterinary Specialists to offer a more personal, yet professional service for pet owners in the local community. Thanks to the funding from NatWest and Lombard, we have been able to create a well-equipped surgery where we can offer the highest level of veterinary orthopaedic expertise.
"We have enjoyed welcoming our first customers over the past month and look forward to continuing to establish ourselves as an expert orthopaedic veterinary clinic, where 100% of referred cases will be managed by a Recognised Specialist."
For more information, visit: https://eoevets.com or telephone 01223 795023
Photo: L-R Karl Simper, relationship manager at NatWest, Martin Owen, co- founder of East of England Veterinary Specialists, Mat Parkhouse relationship manager at NatWest and Mark Bush, co- founder of East of England Veterinary Specialists.
The new briefing will summarise the latest veterinary innovations, resources and research which are of practical value to vets in practice. In other words, only what you strictly need to know.
Need to Know content will be curated by three practising veterinary surgeons: Liz Barton MRCVS (Small Animal, pictured right), Aoife Byrne MRCVS (Equine), and Rachel Tennant MRCVS (Farm Animal). It replaces InDigestion, VetSurgeon.org’s previous monthly newsletter which only linked to the most popular content on the site itself. By contrast, Need to Know summarises developments from all sources.
VetSurgeon.org Editor Arlo Guthrie said: "In these days of information overload, our aim here is to provide busy veterinary surgeons with a really succinct summary of anything that really matters, wherever it comes from."
Need to Know is the result of a new partnership between VetSurgeon.org and Vetsnet, a veterinary wellbeing resource hub set up by Liz to support her colleagues in the profession, and the bulk of any additional advertising revenue generated by the initiative will be ploughed back into Vetsnet.
Arlo added: "Since VetSurgeon launched back in 2008, content has been entirely curated by me. I like to think that has worked reasonably well. Still, having practising veterinary surgeons involved editorially is a big step forward in making sure our content is always useful and relevant."
Anyone subscribed to receive emails from VetSurgeon.org on registration will automatically receive Need To Know.
If you have subscribed, but are NOT receiving emails from VetSurgeon.org, you usually need to log into your email account online and move emails from VetSurgeon.org from your spam or junk folder into your inbox. Some email providers (notably Hotmail) also allow you to ‘whitelist’ emails from certain people and organisations. In that case, add 'vetsurgeon.org' to your whitelist.
If you have unsubscribed from emails from vetsurgeon.org in the past and now want to resubscribe, email support@vetsurgeon.org and we’ll remove you from the exclusion list.
First, the practice carried out an infection control audit to ensure its protocols were robust.
The audit covered the cleaning of clinical areas, non-clinical areas (including offices, reception desks, kltchens and bathrooms), and the personal hygiene of staff members (including hand hygiene and work wear).
Using using the Nationwide Laboratory practice cleanliness screening programme, Rosemullion then conducted environmental swabbing of 10 clinical and non-clinical areas around the practice, including theatre tables, kennels, telephones and door handles, to review contamination levels.
Results showed varying levels of bacterial contamination in both clinical and non-clinical areas.
Finally, Rosemullion assessed personal hygiene and the potential for cross-contamination between patients, colleagues and the environment.
Staff were asked to complete an anonymous ‘Hygiene Self-assessment Questionnaire’ which covered ten areas, including; disinfecting hands; wearing gloves, scrubs with short sleeves and dedicated work shoes, and changing into uniforms when arriving at work.
Amongst clinical staff, there was a 66.75% compliance.
The team then discussed the results, consulted a lab microbiologist and formulated an improvement plan, which included updating the practice cleaning processes (including the cleaning of new touch points), introducing new colleague uniform rules (including changing into uniform upon arrival at work), improving hand hygiene (including providing hand gels for all colleagues) and using sanitising wipes in all office areas.
One month after the policy revisions, swab tests were repeated. They found no bacterial growth in any of the 10 previously swabbed areas.
After two months the colleague questionnaire was run again.
It found clinical colleague compliance over eight personal hygiene indicators had jumped from 66.75% to 92.5% compliance.Abi Redfearn, Senior Veterinary Nurse at Rosemullion, said: “When we opened in 2021, we were keen to monitor our infection control - as part of providing a hospital level of care under the RCVS Practice Standards Scheme.
"With around 100 colleagues and hundreds of patients passing through our doors every week, we are an extremely busy practice – so infection control is paramount in maintaining high clinical standards.“By updating our protocols and taking simple steps - such as providing sanitising materials in high-touch areas – we’ve significantly decreased the risk of environmental contamination.
"Our project is now being used as an example to encourage other practices.”
Leishmaniosis is caused by the parasite Leishmania infantum, which is endemic in some areas of Europe, but not in the UK. The patient in this case had not travelled outside the UK.
In endemic areas, the infection is carried by female sand-flies and spread through sand-fly bites. Transmission has also been reported via dog bites from an infected dog and infected blood transfusions, although the RVC says these routes have not been reported in the UK before.
Dogs with Leishmaniosis display a range of signs that can take months to years to develop after initial infection. Typical signs include:
Weight loss
Lack of energy or enthusiasm
Increased thirst and increased urination
Changes to the skin (particularly around the eyes, ears and feet)
Vomiting or diarrhoea
Lameness due to joint pain
Sudden nose bleeds
Soreness around the eyes
Treatment is available for dogs with leishmaniosis, but infection is difficult to clear and long-term medication is therefore frequently needed. Leishmaniosis can be zoonotic - meaning it can be passed to people in rare situations.
Apparently there is another leishmaniosis case reported in the Veterinary Record this week, this time where the dog was suspected of contracting the disease via sand-flies unintentionally brought back in its owners' luggage following a trip to Spain.
Myles McKenna said: "It is important to take note of this first reported case of likely dog-to-dog transmission of Leishmania infantum in the UK. Historically we had considered this to be a condition affecting dogs with a travel history to areas where Leishmania infantum is endemic. Dog-to-dog transmission in non-endemic areas has previously been reported, for example in the USA, but this case serves as a reminder to UK veterinary surgeons that we must be vigilant for conditions such as Leishmania in non-travelled dogs and that alternative transmission mechanisms do exist."
The Vet Record has published four recommendations to protect dogs and humans in the UK from leishmaniosis.
Photo: Bone marrow cytology showing macrophages with numerous intracellular organisms consistent with Leishmania species amastigotes. Credit Charalampos Attipa
BVA president-elect John Blackwell has found himself on the front page of The Times today, and interviewed on Radio 4's Today programme, with a call to end the practice of slitting animal's throats and allowing them to bleed to death in order to produce kosher and halal meat.
According to the newspaper, 600,000 animals are killed this way every week in the UK.
Mr Blackwell is urging Jews and Muslims to allow meat-producing animals to be stunned before they are killed.
Speaking to The Times, Mr Blackwell said: "As veterinary surgeons, it is one of the most important issues on our radar. This is something that can be changed in an instant."
See other media reports here.
Metacam 40 mg/ml solution for injection for cattle and horses contains 40 mg/ml of meloxicam, and is available in either 50 ml or 100 ml presentations. It is approved for subcutaneous or intravenous use in cattle, and intravenous use in horses.
Boehringer says the introduction comes on the back of a recent large-scale landmark study that found adding Metacam to standard antibiotic therapy for mastitis resulted in a greater first-service conception rate, fewer inseminations required to conceive and a higher probability of pregnancy by 120 days post-calving when compared to cows receiving antibiotic therapy alone1.
Boehringer Ingelheim’s technical manager Kath Aplin said: "By reducing the pain and inflammation caused by mastitis and other conditions, the use of Metacam 40 can result in improvements in cattle health and welfare, and may help limit any reduction in feed intakes. This is central to efficient herd management and productivity."
The company adds that new Metacam 40 mg/ml formulation offers a lower volume dose compared to the existing 20 mg/ml presentation, giving vets more flexibility in their use of Metacam.